The microtubule-associated protein, tau, is the principal component of paired helical filaments (PHFs) in Alzheimer's disease. PHF-tau is highly phosphorylated and a total of 25 sites of phosphorylation have so far been identified. Many of these sites are serine or threonine residues that are immediately followed in the sequence by proline residues, and hence are candidate phosphorylation sites for proline-directed kinases. In vitro, glycogen synthase kinase-3 (GSK-3), extracellular signal-related kinase-1 and -2, and mitogenactivated protein kinases, p38 kinase and c-jun N-terminal kinase, all phosphorylate many of these sites, although with different efficiencies for particular sites. Phosphorylation studies in transfected cells and neurons show that GSK-3 phosphorylates tau more extensively than do these other proline-directed kinases. Mutations in tau have been shown to affect in vitro phosphorylation of
tau by GSK-3. The Arg 406 →Trp (R406W) tau mutation also affects tau phosphorylation in cells.
Identification of phosphorylation sites in paired helical filament (PHF)-tau
Perikaryal aggregates of PHFs form the classical neurofibrillary tangles of Alzheimer's disease. PHFs are also present in dystrophic senile plaque neurites and in neuropil threads. Isolation of PHF as dispersed structures and subsequent analysis with SDS-PAGE results in patterns of four bands of immunoreactive tau (three major and one minor, slower-migrating, band), usually referred to as PHF-tau, as well as a considerable amount of aggregated tau that is present as an immunoreactive smear at the top of the gel [1] [2] [3] . Identification of phosphorylation sites in tau has concentrated mainly on the discrete quadruplet of bands and, until recently, only 20 phosphorylation sites had been identified using mass spectrometry and Edman degradation [4] . However, to date, full sequence coverage of PHF-tau has not been achieved and hence there may be additional, unidentified, phosphorylated residues.
We have developed a modified method for isolating PHF-tau which partially separates the quadruplet of PHF-tau bands; the final product is approximately 50-70% pure. So far, we have subjected the total PHF-tau material to mass-spectrometric analysis. The PHF-tau (in polyacrylamide gel slices) was digested in situ with trypsin or endoproteinase Asp-N and the eluted phosphopeptides were enriched using iron-chelate chromatography. Phosphopeptides were sequenced by nanoelectrospray tandem MS/MS. Besides confirming the majority of previously reported phosphorylation sites, we identified five additional sites, bringing the total number of known sites to 25. These sites are listed in Table 1 (right-hand column).
In vitro phosphorylation of tau
Many residues that are phosphorylated in tau are serines or threonines immediately followed in the sequence by a proline [5] . This makes the sites candidates for proline-directed kinases. We have compared, in vitro, phosphorylation of recombinant 2N4R tau by glycogen synthase kinase (GSK)-3␤, c-jun N-terminal kinase (JNK)-3, p38 mitogen-activated protein (MAP) kinase and extracellular signal-related kinase (ERK)-2.
All kinases phosphorylate tau in vitro to generate epitopes for several monoclonal antibodies that recognize PHF-tau by virtue of its phosphorylated state. These epitopes have been mapped with mutagenesis studies and, of several well-characterized sites in tau, we found that the AT8 epitope (Ser 202 and Thr 205 ) was generated readily by JNK-3, p38 MAP kinase and ERK-2 but only feebly by GSK-3␤ [6, 7] .
We also used mass spectrometry to analyse the tau phosphorylated in vitro by these kinases and found that they phosphorylated the majority of the sites present in PHF-tau in vitro (Table 1) . Sites were identified by chemical sequencing and/or by mass spectrometry [2, 4, 8] except where otherwise indicated. Heparin was required to give detectable phosphorylation on some of the GSK-3␤ sites, and on Ser 356 with ERK-2 (all in vitro data with all four protein kinases are from our own work [6] [7] [8] 
In vitro phosphorylation of mutant tau
The discovery of mutations in the tau gene in cases of frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17) has demonstrated the primary pathogenic potential for abnormalities in tau leading to neurodegeneration [10, 11] . Although several studies have demonstrated differences both in microtubule-binding properties and in the ability to promote microtubule assembly of some mutant forms of tau, it is not yet established how mutations in tau exert their pathogenic effects. We have investigated whether the phosphorylation of several mutants is different from wild-type tau.
Wild-type 2N4R tau and P301L, V337M and R406W mutants on this isoform background were phosphorylated in vitro with GSK-3␤ using [␥-32 P]ATP.
Comparison of the two-dimensional phosphopeptide maps of wild-type tau with those of the mutants revealed that the R406W, but not the P301L or V337M, mutations affected the phosphorylation of tau even though residue 406 is not a phosphorylation site (Figure 1 ). Two phosphopeptide spots were absent in the R406W peptide map: one phosphopeptide contains residue 406, which in wild-type tau is a trypsin cleavage site; the other spot represents phosphorylated Thr 231 and Ser 235 residues which are remote from the site of mutation. Thus this mutation appears to have a marked effect on tau structure, presumably via a conformational change that affects phosphorylation at distant sites.
Phosphorylation of tau in transfected cells and neurons
Since several proline-directed kinases are capable of phosphorylating tau in vitro at many sites shown to be pathophysiologically relevant, it is important to identify which, if any, of these kinases phosphorylates tau in vivo. We therefore undertook a study of tau phosphorylation in transfected cells and in neurons.
HEK-293 cells were stably transfected with GSK-3␤ in the Tet-on system, such that expression of GSK-3␤ occurred when the cells were exposed to doxycycline. On induction the level of GSK-3␤ protein increased and, in the most responsive clones, was increased by ten-fold. GSK-3␤ activity was assayed and also found to increase by six-fold (results not shown). When tau cDNA was transfected into these cells and GSK-3␤ induced, the phosphorylation of tau was modestly increased, as indicated by a small reduction in the mobility of the transfected tau (Figure 2a) , demonstrating that GSK-3␤ phosphorylates tau in a cellular environment.
In a further series of experiments, COS-7 cells were transiently transfected with tau and co-transfected with GSK-3␤, ERK-2, JNK-3 or p38 MAP kinase. Transient transfection results in a greater elevation of kinase protein and, hence, activity compared with the stably transfected cells described earlier. Transfected cells were additionally treated to activate maximally the appropriate transfected kinase [i.e. epidermal growth factor (EGF) for ERK-2, anisomycin for JNK-3 or sorbitol for p38 MAP kinase]. Cells were also triple-transfected to investigate whether there was synergism between these kinases. The phosphory- Figure 1 Phosphopeptide maps of GSK-3␤-phosphorylated recombinant tau showing the differences in phosphorylation patterns between wild-type and three mutant forms of tau. Purified recombinant wild-type and the three mutant forms of tau indicated (longest human isoforms) were phosphorylated in vitro with GSK-3␤ using [␥-32 P]ATP. The tau protein was separated by SDS-PAGE and transferred to nitrocellulose membrane on which the protein was digested with trypsin. The eluted peptides were separated by two-dimensional thin-layer electrophoresis and chromatography and exposed in a phosphorimager to reveal the positions of the phosphopeptides. Two phosphopeptides in the R406W mutant tau were absent and these were sequenced by mass spectrometry and are given below the twodimensional map of this mutant. lation state of tau was assessed by its reduced mobility in SDS-PAGE and reactivity with certain phosphorylation-dependent tau monoclonal antibodies.
We confirmed that GSK-3␤ markedly phosphorylated tau in co-transfected cells (Figures 2b-2d) [12] . ERK-2 also phosphorylated tau but to a lesser extent than GSK-3␤, whereas p38 MAP kinase weakly phosphorylated tau and JNK-3 apparently failed to phosphorylate tau. In triple-transfection experi- ments, ERK-2 and p38 MAP kinase synergized with GSK-3 but JNK-3 had no such effect (Figures 2b-2d) . The inhibitor of ERK-2 activation, PD98059, also inhibited the synergistic effect of ERK-2 with GSK-3␤. In primary cultures of rat brain cortical neurons, tau is endogenously heavily phosphorylated; this phosphorylation can be reduced by lithium treatment to inhibit GSK-3 [13] . Therefore, we treated such cultures with lithium and EGF to activate MAP kinases maximally. There was a modest increase in phosphorylation in response to EGF compared with the control lithiumtreated cells (results not shown).
We conclude that GSK-3␤ is the strongest candidate as a physiological tau kinase; however, ERK-1/ERK-2 are also probably physiological kinases. JNK-3 appears not to be a tau kinase and it remains unclear whether p38 MAP kinase phosphorylates tau in vivo.
Phosphorylation of mutant tau in cells
Since phosphorylation of tau by GSK-3␤ in vitro is affected by the R406W mutation, we investigated whether mutations in tau might affect its ability to be phosphorylated in cells [14] . CHO cells were transfected with wild-type and mutant 0N4R tau isoforms, either alone or co-transfected with GSK-3␤. Western blots of heat-stable proteins were probed with antibodies to determine the phosphorylation state of the tau.
Wild-type tau and V337M, and P301L mutants were all indistinguishable in terms of their SDS-PAGE mobility and their reactivity with TP70, Tau.1, AT8 and PHF-1 antibodies. However, in cells transfected with R406W mutant tau, the tau migrated almost exclusively as a single band, rather than a triplet, due to partial phosphorylation by endogenous kinases. Co-transfection of R406W tau with GSK-3␤ resulted in increased phosphorylation similar to wild-type tau. Thus, certainly with physiologically normal levels of protein kinases, the R406W mutation affects the phosphorylation state of tau [14] . 
